Neurocrine Biosciences Inc (NASDAQ: NBIX) has reported earnings for its first fiscal quarter (ending March 31) of $0.43 versus a loss $-0.79 for the same period a year ago. This result fell short of the consensus estimate of $1.52 by $-1.09. For the latest four quarters through March 31, E.P.S. were $3.76 versus $0.67 for the same period a year ago — an increase of 461%.
Recent Price Action
Neurocrine Biosciences Inc (NASDAQ: NBIX) stock closed at $143.03 on 5/1/24 after a large increase of 4.0%. Moreover, unusually high trading volume at 180% of normal accompanied the advance. The stock has risen 2.1% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
NBIX is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Neurocrine Biosciences has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Neurocrine Biosciences has a neutral Appreciation Score of 44 but a good Power Rating of 79, resulting in the High Neutral Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment